Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon

Table 3 Empirical and definitive antimicrobial therapy received

Antimicrobial therapy	n (%)
Empirical antimicrobial therapy (N = 111)^a
Monotherapy vs combination therapy
Monotherapy	64 (57.6)
Combination	47 (42.3)
Empirical antimicrobial therapy initiated
Meropenem	64 (57.6)
Colistin	59 (53.1)
Vancomycin	27 (24.3)
Piperacillin/tazobactam	15 (13.5)
Levofloxacin	13 (11.7)
Teicoplanin	10 (9.2)
Ceftazidime	5 (4.5)
Others^b	7 (6.3)
Definitive antimicrobial therapy (N = 87)^c
Colistin	80 (92)
Meropenem	4 (4.6)
Tigecycline	3 (3.4)

^aAs multiple responses were recorded, numbers do not add up to 111
^bCefepime, amikacin, ciprofloxacin, imipenem/cilastatin, ceftriaxone, clindamycin, and ampicillin/sulbactam
^cTwenty-four patients out of the 111 died during the empirical therapy

ISSN: 2047-2994